Showing results (361-370 of 380) with videos related to
Sort By:
Pageof 38
Biorxiv : the Preprint Server for Biology|June 12, 2026
Hierarchical classification of immune cell transcriptomes at population-scaleChristopher Beltz, Zekai Qiu, Leon Sadowski, et al.The Lancet. Oncology|May 14, 2021
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort studyInes Pires da Silva, Tasnia Ahmed, Irene L M Reijers, et al.European Journal of Cancer (Oxford, England : 1990)|August 30, 2024
Early versus late response to PD-1-based immunotherapy in metastatic melanomaGeorg C Lodde, Fang Zhao, Rudolf Herbst, et al.British Journal of Cancer|October 22, 2020
Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysisPrachi Bhave, Lalit Pallan, Georgina V Long, et al.European Journal of Cancer (Oxford, England : 1990)|March 23, 2025
First-line checkpoint inhibitor therapy in metastatic acral lentiginous melanoma compared to other types of cutaneous melanoma: A multicenter study from the prospective skin cancer registry ADOREGSören Reinhard, Jochen Sven Utikal, Anne Zaremba, et al.Journal for Immunotherapy of Cancer|June 10, 2022
Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREGCindy Franklin, Peter Mohr, Leonie Bluhm, et al.European Journal of Cancer (Oxford, England : 1990)|August 1, 2025
Sex-specific survival in advanced metastatic melanoma - a DeCOG study on 2032 patients of the multicenter prospective skin cancer registry ADOREGAnna-Sophia Leven, Triinu Peters, Luisa Sophie Rajcsanyi, et al.European Journal of Cancer (Oxford, England : 1990)|January 21, 2023
Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanomaSelina K Wong, Steven M Blum, Xiaopeng Sun, et al.Nature Medicine|December 4, 2019
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaDavid Liu, Bastian Schilling, Derek Liu, et al.European Journal of Cancer (Oxford, England : 1990)|January 23, 2024
The side effect registry immuno-oncology (SERIO) - A tool for systematic analysis of immunotherapy-induced side effectsCarolin Ertl, Theresa Ruf, Dirk Mentzer, et al.Pageof 38